ReviewResearch and reports in urology2014
OnabotulinumtoxinA for the treatment of overactive bladder.
Review in Research and reports in urology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06437899 (Evaluation of Efficacy and Patient Satisfaction Using Local Anaesthesia Versus Sedoanalgesia for Intradetrusor Botulinum-Toxin A Injection for the Treatment of Idiopathic Overactive Bladder), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Efficacy and Patient Satisfaction Using Local Anaesthesia Versus Sedoanalgesia for Intradetrusor Botulinum-Toxin A Injection for the Treatment of Idiopathic Overactive Bladder: a Randomized Controlled Non-inferiority Trial
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Expert Opinions on Best Practices for Overactive Bladder Management with onabotulinumtoxinA.Toxins · 2025Article
- Sexual Dysfunction in Patients with Overactive Bladder Syndrome Treated with Botulinum Toxin.Journal of clinical medicine · 2024Article
- Article
- Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2022Review
- Emerging Opportunities in Human Pluripotent Stem-Cells Based Assays to Explore the Diversity of Botulinum Neurotoxins as Future Therapeutics.International journal of molecular sciences · 2021Review
- PGE2 receptors in detrusor muscle: Drugging the undruggable for urgency.Biochemical pharmacology · 2021Review
- Alternative Methods for Testing Botulinum Toxin: Current Status and Future Perspectives.Biomolecules & therapeutics · 2020Review
- Application of methylene blue as an improvement of the injection technique of botulinum toxin A in the treatment of refractory idiopathic overactive bladder: prospective, single-blind (patient-blind), randomized trial.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2019Article
- Non-invasive evaluation of botulinum-A toxin treatment efficacy in children with refractory overactive bladder.International urology and nephrology · 2018Article
- OnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2017Article
- Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.International journal of clinical practice · 2017Article
- Review
- Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome.International neurourology journal · 2015Review
- Current and potential urological applications of botulinum toxin A.Nature reviews. Urology · 2015Review
- Symptomatic management in multiple sclerosis.Annals of Indian Academy of Neurology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OnabotulinumtoxinA injection is a safe and effective treatment for adults with refractory overactive bladder. There is sufficient level 1 evidence to support offering onabotulinumtoxinA injections as a second-line treatment to patients who have failed behavioral therapy and oral medications such as antimuscarinics and β3 agonists. An intradetrusor injection of 100 U of onabotulinumtoxinA is likely the optimal dose to balance risks and benefits, and this is the dose approved by the US Food and Drug Administration. Improvement in urgency urinary incontinence episodes, as well as symptom scores and quality of life, were seen in around 60%-65% of patients, and were significantly improved compared with those on placebo. Most studies have reported a duration of symptom relief ranging from 6 to 12 months, with repeat injections being safe and efficacious. Overall, the risk of urinary retention was around 6% across the study populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.